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Background: Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic ane-
mia,  which often manifests as peripheral blood cytopenias and thrombosis.
Objective: The aim of this study is to describe a Brazilian population of paroxysmal nocturnal
hemoglobinuria patients.
Methods: One hundred and three paroxysmal nocturnal hemoglobinuria cases were retro-
spectively reviewed and the clinical presentation, thrombosis, survival, and clone size were
assessed. Diagnosis was established by ﬂow cytometry.
Results: Fifty-two male and 51 female patients with a median age of 24.1 years (5.5–62 years)
were studied. Clinical symptoms included hemoglobinuria (18.4%), infection (46.6%) and
thrombosis (16.5%), and 80.6% had pancytopenia. Patients were classiﬁed as classic parox-
ysmal nocturnal hemoglobinuria (10), paroxysmal nocturnal hemoglobinuria with aplastic
anemia (39), and paroxysmal nocturnal hemoglobinuria with subclinical features and aplas-
tic  anemia (54). There were signiﬁcant differences in terms of median age, size of clone,
clinical symptoms, and peripheral blood cell counts between the three subcategories. The
clone  size in erythrocytes and granulocytes were respectively 0.04% (range: 0–18%) and 7.3%
(range: 0.3–68.7%) in patients with subclinical features and aplastic anemia, 15.8% (range:
0–99.7%) and 63.0% (range: 1.7–99.8%) in patients with aplastic anemia alone, and 82.2%
(range: 0–99.85%) and 98.0% (81.3–100.0%) in Classic disease. Statistical differences were
identiﬁed for platelets (p-value = 0.001), lactate dehydrogenase (p-value = 0.002) and the clone
size (p-value < 0.001) in patients who suffered thrombotic events compared to those who did
not. Overall survival was 81.7%, with patients with subclinical features and aplastic anemia
having lower overall survival (76.5%).
Conclusion: This retrospective review of 103 patients over an 11-year period represents the
largest collection of paroxysmal nocturnal hemoglobinuria cases from a single center in
Brazil. Flow cytometry showed that a larger clone was associated with classical symptoms
and increased risk of thrombosis, even in patients with bone marrow failure, whereas a
smaller clone was associated with bone marrow aplasia.© 2015 Associac¸ão Bra
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aroxysmal nocturnal hemoglobinuria (PNH) is a rare,
cquired, stem cell disorder characterized by hemolytic
nemia, bone marrow failure, and an acquired throm-
ophilic state.1–4 Manifestations of the disease are related
o complement-mediated intravascular hemolysis due to the
ack of glycosyl phosphatidylinositol-anchored complement
egulatory proteins (GPI-AP), CD55 and CD59 on red blood
ells.5,6 Patients with PNH may present not only with a
ide range of clinical manifestations such as weakness,
allor, and asthenia due to hemolysis, but also abdominal
ain, dysphagia, or pulmonary hypertension.2–4 Thrombosis,
ften occurring at unusual sites, is a major life-threatening
isk for patients with PNH.1–4 Ten-year risk of thrombo-
is has been associated with the PNH clone, as patients
ith large PNH clones (>50%) had 44% of 10-year risk com-
ared with 5.8% in patients with small clones.7 A frequent
ssociation between PNH and aplastic anemia (AA) has
een described, with two potential patterns of evolution:
rogressive marrow failure in patients without detectable
NH clones or AA in patients in whom a PNH clone is
etected.8–10
Diagnosis of PNH has improved over the years with the
doption of modern technologies. Two decades ago the Ham
est, which is based on increased sensitivity of PNH-affected
ed blood cells to complement-mediated lysis, was used.5,11
oday, the Ham test has usually been substituted by the
ore  sensitive, informative and less cumbersome ﬂow cyto-
etric assay (FCM), which uses antibodies directed against
he GPI-AP.11–14 PNH cells are characterized by GPI-AP deﬁ-
iency on the cell surface due to an acquired mutation of
he phosphatidylinositol glycan-class A (PIGA) gene in one or
ore hematopoietic stem cells.6,11,12 The development of
CM-based testing has allowed the detection of small PNH
lones, which would otherwise not be evident.13,15 PNH clones
re also detected in the setting of bone marrow failure, and
bout 40–50% of AA patients have a PNH clone detected at
he time of diagnosis.8,15,16 The mechanism by which the
xpansion of PNH cells occurs in AA remains unclear; one
ypothesis is that PNH cells have a proliferative advantage
ver non-PNH cells by an immune selection mechanism.9,10
he presence of a PNH clone has been reported to be
redictive of a response to immune suppression in AA15
ut other authors did not observe this ﬁnding.16 For opti-
um management, the contribution of both hemolysis and
arrow failure to the complex anemia of PNH should be
etermined.1
The objective of this study was to assess the clinical pre-
entation of PNH patients at the time of diagnosis, as well
s report complications, such as thrombosis, survival, dif-
erence between subcategories and clinical signiﬁcance of
he PNH clone size. Patients were assigned to one of the
hree subcategories, namely Classic PNH, PNH/AA syndrome,
nd subclinical PNH (PNH-sc/AA) to explore the differences
etween these categories. Furthermore, the size of PNH clone
as evaluated in the entire cohort and in each subcategory
o assess whether the size of PNH clones was associated with
ome of the clinical features of PNH.2 0 1 5;3 7(2):90–97 91
Methods
Patients  and  study  design
One hundred and three PNH clone cases referred to a tertiary
medical center in Brazil from December 1999 through Decem-
ber 2011 were retrospectively reviewed. A total of 398 patients
were screened for the PNH clone using a FCM assay.5,14 The
diagnosis of PNH was established by detecting a GPI-AP deﬁ-
cient clone greater than 0.1%, with at least two  cell lineages
showing GPI deﬁcient populations. The study included 103
patients who had demonstrated the presence of a PNH clone
and had available clinical data. The date of PNH diagno-
sis was based on the ﬁrst positive FCM analysis. Patients
with co-morbid AA were subclassiﬁed as severe or non-severe
according to published criteria.17,18
Multiparameter  ﬂow  cytometry
The diagnosis of PNH was established by the detection of an
unequivocal positive PNH clone by multicolor FCM assay5,11
using a FACSCalibur® cytometer (BD Biosciences, San Jose,
USA) and CellQuest Pro software (BD Biosciences, San Jose,
USA). The proteins studied were CD55 and CD59 on red cells,
neutrophils and monocytes; CD16, CD24 and CD66b on neu-
trophils and CD14 on monocytes. PNH clones were deﬁned by
the presence of GPI-AP deﬁcient cells at a frequency greater
than 0.1% of neutrophils, monocytes and red cells, and the
proportion of GPI-AP deﬁcient cells (clone size) was deﬁned by
the highest level of these cells lacking GPI-anchored proteins.
Debris was thresholded out, and at least 50,000 events
in leukocyte tubes and 20,000 events in red cell tubes were
collected and analyzed using Paint-a-gate® (BD Biosciences,
San Jose, USA) or InﬁnicytTM (Cytognos, Salamanca, Spain)
software (for samples tested after January 2009). Red cells
and granulocytes were identiﬁed based on forward and side
scatter, and by staining with CD41a FITC and CD45 PercP,
respectively. The gates used to deﬁne GPI negative populations
were established by using normal red cells and granulocytes
as controls.
Subcategories  of  paroxysmal  nocturnal  hemoglobinuria
patients  at  diagnosis
Patients were assigned to one of the three subcategories based
on the recently proposed PNH working clinical classiﬁcation1:
(I) The Classic PNH subcategory included patients with clin-
ical and laboratory evidence of intravascular hemolysis
(such as hemoglobinuria, hemoglobinemia, and elevated
LDH and bilirubin) but no evidence of bone marrow fail-
ure;
(II) Patients in the PNH/AA subcategory were deﬁned by the
presence or a history of bone marrow failure in conjunc-
tion with clinical and laboratory evidence of intravascular
hemolysis;
(III) Patients in the subclinical PNH (PNH-sc/AA) subcategory
were identiﬁed by the presence of bone marrow failure
but without clinical or laboratory evidence of hemolysis.
moter. 2 0 1 5;3 7(2):90–97
Table 1 – Patient characteristics (n = 103).
Characteristic
Gender, male – n (%) 52 (50.5)
Median age – years (range) 24.1 (5.5–62.0)
Clinical symptoms at presentation – n (%)
Asthenia/fatigue 98 (95.1)
Infection/fever 48 (46.6)
Hemoglobinuria 19 (18.4)
Bleeding (petechiae and ecchymosis) 33 (47.1)
Abdominal pain 33 (32.0)
Jaundice 26 (25.2)
Renal insufﬁciency 14 (13.6)
Thrombosis 17 (16.5)
Hemolysis 24 (23.3)
Peripheral blood abnormalities at presentation – n (%)
Anemia alone 4  (3.9)
Anemia and thrombocytopenia 12 (11.6)
Anemia and neutropenia 4 (3.9)
Pancytopenia 83 (80.6)
Bone marrow biopsy – n (%)
Aplasia (<5%) 52 (50.5)92  rev bras hematol he
The criteria for bone marrow failure included bone marrow
hypoplasia (cellularity < 50%) and at least two of the follow-
ing three laboratory abnormalities: hemoglobin level <12 g/dL,
absolute neutrophil count <1.50 × 109/L, and platelet count
(PLT) <100 × 109/L. Pancytopenia was considered when the
three hematopoietic lineages were affected. Haptoglobin val-
ues were not used in this study.
Statistical  analysis
Overall survival (OS) was calculated from the date of diagno-
sis to the date of death or the date of last follow-up. Survival
analysis was performed using the Kaplan–Meier method. The
distributions of the presentation of characteristics were com-
pared between the three subcategories and between Classic
PNH and PNH-sc/AA by the chi-squared or Fisher’s exact test as
necessary for categorical variables, and by the Kruskal–Wallis
(three subcategories) or Mann–Whitney (two groups) test for
continuous variables. The percentages of GPI-AP deﬁcient red
blood cells and granulocytes were compared using Student’s
t-test. All statistical analyses were performed using the Statis-
tica v.8 program. A p-value <0.05 was considered statistically
signiﬁcant.
Ethical  approval
The Ethics Committee of the Hospital de Clinicas, Universi-
dade Federal do Paraná, Brazil approved the study.
Results
Patient  characteristics
Of the 398 patients tested, 125 (31.4%) had a detectable PNH
population. Of these, 103 (51 male and 52 female), who had
clinical data available, were studied. The median age at pre-
sentation was 24.1 years (range: 5.5–62.0 years). There were
24 patients below the age of 18 years (range: 5.5–17.9 years;
median: 14.7). All these young patients were in the aplastic
groups (11 HPNsc/AA and 13 HPN/AA).
Hemoglobinuria was identiﬁed during monitoring in 43
(41.7%) patients, while it was the initial symptomatic man-
ifestation in only 19 (18.4%) patients. The frequencies of
infections and bleeding were 46.6% and 47.1%, respectively.
Ninety-eight patients (95.1%) presented with asthenia, 33
(32.0%) with abdominal pain, and 14 (13.6%) with renal insuf-
ﬁciency; 17 (16.5%) developed thrombosis during monitoring
and 49 patients (47.6%) had documented hemolysis. Twenty-
six patients (25.2%) with aplasia at diagnosis developed the
PNH clone and hemolysis in a median of 2.35 years after diag-
nosis. Of these patients, eleven (10.7%) developed hemolysis
ﬁve years after the diagnosis of aplasia.
Peripheral blood abnormalities were present in 101
patients: 83 (80.6%) had pancytopenia, 12 (11.6%) anemia
and thrombocytopenia, and four (3.9%) had anemia and
leukopenia. The median hemoglobin level was 8.8 g/dL (range:
3.8–14.5 g/dL), the median absolute neutrophil count was
0.94 × 109/L (range: 0.26–1.45 × 109/L) and the median platelet
count was 25 × 109/L (range: 2–294 × 109/L). The median LDHHypocellular bone marrow (6–49%) 38 (36.9)
Normo or hypercellular bone marrow (≥50%) 13 (12.6)
concentration was 328 U/L (range: 30–7970 U/L; normal range
190–240 U/L). Ninety patients (87.4%) had hypocellular bone
marrow.
Patients included in this study were divided into the sub-
categories of Classic PNH (10 patients), PNH/AA (39 patients),
and PNH-sc/AA (54 patients) based on the proposed PNH work-
ing clinical classiﬁcation.1 The initial characteristics of the
subgroups are summarized in Table 1.
The median ages of PNH-sc/AA, PNH/AA and Classic
PNH patients were 25.1, 21.5 and 34.7 years, respec-
tively (p-value = 0.016). The clinical symptoms of hemolysis,
hemoglobinuria and thrombosis were higher in the hemolytic
forms of PNH (PNH/AA and Classic PNH) than in PNH-sc/AA
(p-value < 0.001), whereas infection and fever were higher in
the PNH-sc/AA group (p-value < 0.001). The median numbers
of neutrophils and platelets were signiﬁcantly lower in the
aplastic groups than in the Classic PNH group (p-value for both
<0.001). On the other hand, the Classic PNH group had higher
hemolytic markers, such as LDH (p-value = 0.001), reticulocyte
count (p-value <0.001) and bilirubin levels (p-value <0.001 –
Table 2).
Correlation  of  paroxysmal  nocturnal  hemoglobinuria  clone
with clinical  characteristics
FCM data showed that larger PNH clones were associated
with classical PNH and thrombotic events, while smaller PNH
clones were associated with bone marrow aplasia. At diagno-
sis PNH clone sizes in red cells, granulocytes and monocytes
were signiﬁcantly different between the three clinical sub-
categories (p-value <0.001) for all the studied monoclonal
antibodies (CD55, CD59, CD14, CD16, CD24 and CD66b). The
median PNH clone percentages in red cells were 0.04% (range:
0–18.0%), 15.8% (range: 0–99.7%) and 82.2% (range: 0–99.85%)
in PNH-sc/AA, PNH/AA and Classic PNH, respectively (p-value
<0.001). Moreover, the median PNH clone percentages in
rev bras hematol hemoter. 2 0 1 5;3 7(2):90–97 93
Table 2 – PNH subgroup characteristics.
PNH category Total
(n = 103)
a – PNH-sc/AA
(n = 54)
b – PNH/AA
(n  = 39)
c  – Classic
PNH (n = 10)
p-Valuea
(a × b × c)
p-Value
(a  × b)
p-Value
(a × c)
p-Value
(b × c)
Age 24.1 (5.5–62.0) 25.1 (7.5–62.0) 21.5 (5.5–49.4) 34.7 (26.7–55.9) 0.016 0.322 0.017 0.004
Asthenia/fatigue 98 (95.1%) 51 (94.4%) 37 (94.9%) 10 (100%)
Infection/fever 48 (46.6%) 23 (42.6%) 25 (64.1%) 0 (0%) 0.001
Hemoglobinuria 43 (41.7%) 4 (7.4%) 30 (76.9%) 9 (90%) <0.001
Thrombosis 17 (16.5%) 2 (3.7%) 9 (23.1%) 6 (60%) <0.001
Hemolysis 49 (47.6%) 0 (0%) 39 (100%) 10 (100%) <0.001
Hemoglobin (g/L) 88 (38–145) 80 (38–132) 94 (45–145) 89.5 (51–117) 0.062a
Leucocytes
(×103/L)
2970 (1140–8800) 2675 (1140–8800) 3110 (1470–7780) 4490 (1600–6680) 0.008a 0.05 0.005 0.106
ANC (×109/L) 0.94 (0.26–4.95) 0.825 (0.26–4.66) 1.06 (0.59–4.95) 2.724 (0.16–3.90) 0.000a 0.084 0.000 0.001
Platelets (×109/L) 25 (2–294) 20 (2–99) 27 (3–137) 1815 (6–294) <0.001a 0.041 0.00 0.00
ARC (×109/L) 53.8 (2.4–437) 35.4 (2.4–153) 70.8 (3.2–214) 240 (78–437) <0.001a 0.002 0.00 0.00
LDH (U/L) 328.5 (30–7690) 234 (30–783) 517 (187–4550) 1608 (328–7690) 0.001b 0.002 0.00 0.004
Bilirubin (mg/dL) 0.9 (0.17–7.1) 0.7 (0.17–4.93) 1.06 (0.39–3.32) 2.54 (0.39–7.1) <0.001a 0.004 0.00 0.00
Bone marrow
cellularity
5%  (0–100%) 5% 10% 70% <0.001a 0.00 0.00 0.00
Flow cytometry
Neutrophil
clone size
(median)
25.2  (0.3–100) 7.3 (0.3–68.7) 63 (1.7–99.8) 98 (81.3–100) <0.001a 0.00 0.00 0.001
Erythrocyte
clone size
(median)
2.2  (0–92.2) 0.04 (0–18) 15.8 (0–99.7) 82.2% (0–99.85) <0.001b 0.00 0.00 0.018
a: PNH-sc/AA group; b: PNH/AA group; c: Classic PNH group.
ANC: absolute neutrophil count; ARC: absolute reticulocyte count; LDH: lactate dehydrogenase.
g
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Fa ANOVA p < 0.05.
b Kruskal–Wallis, p < 0.05.
ranulocytes were 7.3% (range: 0.3–68.7%), 63.0% (range:
.7–99.8%) and 98.0% (range: 81.3–100.0%) in PNH-sc/AA,
NH/AA and Classic PNH, respectively (p-value <0.001 –
igures 1–3).
hrombotic  eventseventeen patients presented with thrombotic events: six in
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igure 1 – Median percentages of paroxysmal nocturnal hemogloin the PNH-sc/AA group. There were ﬁve cases of deep vein
thrombosis (DVT), ﬁve abdominal thromboses, ﬁve arterial
thromboses with ischemic stroke, one sinus venous thrombo-
sis and one renal vein thrombosis. Two PNHsc/AA patients had
DVT despite the absence of hemolytic symptoms, and died.
Four of the PNH/AA patients died due to thrombotic events.
Regarding the PNH clone, clones larger than 50% were seen
in neutrophils of 13 (76.5%) patients (p-value <0.001), and in
erythrocytes of six (35.3%) patients (p-value = 0.005 – Table 3).
tages in flow cytometry
AA/PNH (n=39) Classic PNH (n=10)
63 98
15.8 82.2
binuria clone in erythrocyte and neutrophil clones.
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Figure 2 – Number of patients with predominantly small erythrocyte clones in paroxysmal nocturnal hemoglobinuria with
subclinical features and aplastic anemia, intermediate clones in paroxysmal nocturnal hemoglobinuria with aplastic
anemia and large clones in classic paroxysmal nocturnal hemoglobinuria.
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Figure 3 – Number of patients with predominantly small granulocyte clones in paroxysmal nocturnal hemoglobinuria with
subclinical features and aplastic anemia, intermediate in paroxysmal nocturnal hemoglobinuria with aplastic anemia and
large in classic paroxysmal nocturnal hemoglobinuria.
The differences between patients with or without throm-
botic events are shown in Table 4. There were statis-
tically signiﬁcant differences in the number of platelets
(p-value = 0.001), LDH (p-value = 0.002) and in median percent-
ages of the PNH clone in neutrophils (p-value <0.001) and
erythrocytes (p-value = 0.008). The median neutrophil PNH
clone in thrombotic patients was 92.7% (range: 3.4–100%)
vs. 21.8% (range: 0.25–99.9%) in non-thrombotic patients.
Table 3 – Paroxysmal nocturnal hemoglobinuria neutrophil and
PNH clone
<10%
PNH
Neutrophil clone size – n (%) 1 (5.9) 3 (
Erythrocyte clone size – n (%) 5 (29.4) 6 (The median erythrocyte PNH clone was 31.8% (range:
0.0–97.1%) vs. 1.2% (range: 0.0–92.2%) in thrombotic and non-
thrombotic patients, respectively. The bone marrow cellular-
ity, hemoglobin concentration, leukocyte count and absolute
reticulocyte count were similar between the two groups.
There were six deaths among patients with thrombotic
events (35.3%), and eight (9.3%) among the non-thrombotic
group.
 erythrocyte clones in thrombotic patients.
 clone
10–50%
PNH clone
≥50%
p-Value (2
test)
17.6) 13 (76.5) <0.001
35.3) 6 (35.3) 0.005
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Table 4 – Characteristics of patients with and without thrombosis.
Thrombosis Yes No p-Value (2 test)
Bone marrow cellularity – % 10 5 0.166
Hemoglobin (g/L) 8.8 6.5 0.682
Leukocyte (×103/L) 3500 2600 0.663
ARC (×109/L) 78.2 48.6 0.046
Platelets (×109/L) 67.0 31.5 0.001
LDH (U/L) 607 299 0.002
Neutrophil clone size (median) – % 92.7% 21.5% <0.001
Erythrocyte clone size (median) – % 31.8% 1.2% 0.008
Death – n (%) 6/17  (35.3%) 8/86 (9.3%) <0.001
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urvival  and  treatment
s a retrospective study, the cohort of patients received
ifferent treatments depending on the physician and time
riteria. The majority of patients (81.9%) of aplastic groups
PNH-sc/AA and PNH/AA) received cyclosporine A-based
mmunosuppressive therapy with or without corticosteroids
ome time during the follow-up, and 12 patients (12.7%)
eceived anti-human thymocyte immunoglobulin immuno-
uppressive therapy. Hematopoietic stem cell transplantation
HSCT) was performed in 27 patients (28.7%), the majority of
hom were in the PNH-sc/AA group. Nine PNH/AA and two
lassic PNH patients received HSCT due to hemolytic symp-
oms. Eculizumab was introduced in 2010, and ﬁve patients
eceived this drug until the conclusion of the study.
The median follow-up period for all patients was 49.2
onths (range: 2.4–310 months), with an OS of 81.7% at ten
ears after diagnosis. There was a slight difference in survival
etween PNH-sc/AA and the other two groups (76.5% vs. 87.9%;
-value = 0.112). In total 14 patients died, nine in the PNH-
c/AA group and ﬁve in the PNH/AA group. The causes of death
ere sepsis (six patients), pulmonary thromboembolism (four
atients), mesenteric thrombosis (two patients), severe graft-
ersus-host disease (GVHD) after HSCT (one patient) and
udden death (one patient). No death was reported in the clas-
ical PNH group by the end of the follow-up period.
iscussion
NH is a rare acquired disorder of hematopoietic stem
ells, which is characterized by a highly variable clinical
ourse, including intravascular hemolysis, bone marrow fail-
re syndromes and thrombosis.1–3 The natural history of PNH
as been widely discussed in the literature in retrospective
eries,3,4,8,9,16,19,20 which conﬁrm the association between PNH
nd bone marrow syndromes. The proportion of patients with
one marrow hypoplasia who develop clinical or subclinical
NH varies from 22%8 to 40%.16 Some studies that used Ham’s
est to diagnose PNH showed that 5–10% of patients with Clas-
ic PNH develop pancytopenia.2,4
The current study identiﬁed 103 patients with a PNH clone,
7.4% of whom had hypoplastic marrow at diagnosis. PNH-
ssociated cytopenias were common and recurrent infections
nd bleeding were seen in 46.6% and 47.1% of patients, respec-
ively. The high prevalence of bone marrow failure may bea result of an ascertainment bias explained by the fact that
the Hospital de Clinicas in Curitiba receives cases of aplasia
from many  regions of Brazil. For the same reason the majority
of patients (81.9%) received immunosuppressive therapy and
28.7% received HSCT.
Patients included in this study were assigned to three
subcategories based on the proposed PNH  working clinical
classiﬁcation,1 namely Classic PNH, PNH/AA, and PNH-sc/AA.
As expected, the clinical symptoms of hemolysis, hemoglobin-
uria and thrombosis were higher in the hemolytic forms of
PNH (PNH/AA and Classic PNH) than in PNH-sc/AA, whereas
infection and fever were higher in the latter group. There
were signiﬁcant differences in terms of peripheral blood cell
counts between the three subcategories, especially between
the Classic PNH and PNH-sc/AA subcategories. The median
PNH clone size was also signiﬁcantly different between the
three clinical subcategories at diagnosis. On the other hand,
eight patients in the PNH/AA group presented with intense
hemolytic symptoms and PNH clones greater than 50%,
despite the hypocellular bone marrow, suggesting an over-
lap between the subgroups. This fact could be explained by
the heterogeneity of the sample and the disease, and by the
retrospective bias of this study.
PNH mainly presents as a disease of adults, but the median
age found in the current series was lower than in the literature
(24.1 vs. 34.2 years).2,3,19 This difference can be explained by
the proportion of aplastic patients who evolved with the PNH
clone (PNH-sc/AA) after a long period of time in our series.
However, if the median age of the Classic PNH group is con-
sidered, it is similar to other studies.4,16,20
In the last decade, the detection of GPI-AP deﬁcient cells by
ﬂow cytometry greatly increased the sensitivity of detecting a
PNH clone in both red blood cells and leukocytes, minimizing
the effects of red cell transfusions on estimating clone size.5,11
Since the introduction of FCM, quantitative and kinetic differ-
ences of GPI-AP deﬁcient clones have been reported between
PNH patients with and without marrow failure. The litera-
ture suggests that the clinical manifestations due to chronic
hemolysis in PNH appear to be more  common in patients
with large populations of cells deﬁcient in GPI proteins.1,19–21
Pu et al. showed a direct relationship between the size of
PNH clone and the development of intravascular hemolysis
in patients with aplasia.19 In the current study large granulo-
cyte PNH clones were found in Classic PNH (98.0%), medium
clones in PNH-AA (63.0%) and small PNH clones in PNH-
sc/AA (7.3%), suggesting that larger PNH clones (>50%) are
mote
r
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associated with increased risks of hemoglobinuria and throm-
bosis, whereas small PNH clones (<50%) are associated with
bone marrow failure.
In this study, life-threatening thrombotic complications
were present in 16.5% of patients, with six deaths occur-
ring in this group (35.3% vs. 9.3% in the non-thrombotic
group). All three subcategories had at least one episode of
thrombosis. Two PNHsc/AA patients had DVT despite the
absence of hemolytic symptoms, and died. Four of the PNH/AA
patients died due to thrombotic events. PNH clones larger than
50% were seen in the granulocytes of 13 (76.5%) thrombotic
patients, which is consistent with the literature that says that
a clone size greater than 50% is associated with increased risk
of thrombosis and the need of primary anticoagulation.7,21
In the current cohort the size of the PNH clone was greater
in patients with thrombosis for both neutrophils (92.7% vs.
21.5%) and erythrocytes (31.8% vs. 1.2%).
The OS ten years after diagnosis was 81.7% in this study,
which is slightly higher than other studies,20 which reported
77.6% at 10 years. Infection and thrombotic events were iden-
tiﬁed as the main causes of death. There were 14 deaths
(13.5%), 12 of which were attributable to PNH or aplasia; of
the deaths, six (42.8%) were secondary to thrombosis. With
regard to the disease subcategories, the long-term outcomes
were similar between patients in the hemolytic PNH subcate-
gories, but slightly different in PNH-sc/AA group, probably due
to a high risk of infection. Further studies may shed insights
into the hypothesis that the PNH-sc/AA subcategory might be
a separate disease entity from Classic PNH.1,5,22
Conclusion
This retrospective study of 103 PNH patients over an 11-year
period represents the largest collection of such patients from
a single center in Brazil. The results conﬁrmed the suggestion
that PNH is not a simple binary diagnosis and both ﬂow cyto-
metric characterization of GPI-AP expression on peripheral
blood cells and marrow analysis are required for comprehen-
sive disease classiﬁcation. FCM data from this study shows
that larger PNH clones are associated with classical PNH symp-
toms and increased risk of thrombosis, even in patients with
bone marrow failure, whereas smaller PNH clones are associ-
ated with bone marrow aplasia.
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